Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04852679

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs — PALACE  

Gastroenteropancreatic Neuroendocrine Tumor Clinical Trial

Official title:
A Phase 3, Single-arm, Open-label, Multicentre Study to Assess the Efficacy and Safety of Deep Subcutaneous Injections of Lanreotide Autogel® 120 mg Administered Every 28 Days in Chinese Participants With Unresectable, Locally Advanced or Metastatic Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs)

Clinical Trial Summary

This study will be conducted to support the registration of the lanreotide Autogel 120 mg formulation in China for the treatment of GEP-NETs and treatment of clinical symptoms of NETs. The study will include a screening period of up to 4 weeks followed by a 48-week intervention period. After completion of the main study period, approximately five participants will continue in a self/partner injection cohort with lanreotide Autogel 120 mg every 28 days for 24 weeks.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04852679
Study type Interventional
Source Ipsen
Contact
Status Completed
Phase Phase 3
Start date May 24, 2021
Completion date January 13, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06155318 - 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
Terminated NCT01994213 - A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor Phase 2
Active, not recruiting NCT03980925 - Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Phase 2
Recruiting NCT02611024 - Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors Phase 1/Phase 2
Enrolling by invitation NCT05064150 - Neuroendocrine Tumors - Patient Reported Outcomes
Active, not recruiting NCT04727723 - Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
Recruiting NCT06256705 - Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort N/A
Active, not recruiting NCT05477576 - Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Phase 3
Recruiting NCT04609592 - Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery Phase 1
Recruiting NCT05701241 - Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients Phase 4
Completed NCT02948946 - Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
Withdrawn NCT04915144 - 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs Phase 2
Recruiting NCT04986085 - Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
Recruiting NCT05262556 - NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas Phase 1
Completed NCT03017690 - Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)